Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study.
about
Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young menDistinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects.Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome.Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults.Relation of vascular growth factors with CT-derived measures of body fat distribution: the Framingham Heart Study.A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C.Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study.Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease.Coronary angiogenesis during experimental hypertension: is it reversible?Soluble fms-Like Tyrosine Kinase 1 as a Link Between Angiogenesis and Endothelial Dysfunction in Pediatric Patients With β-Thalassemia Intermedia.Sflt-1 in heart failure: relation with disease severity and biomarkers.VEGF is indirectly associated with NO production and acutely increases in response to hyperglycaemia(1).Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1, and the severity of coronary artery disease.Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis
P2860
Q33689418-7167F05E-E504-42A0-A63D-9673430C08D6Q34113726-41A63AAB-B3EB-4ACB-8551-F9B9E8CEEA7AQ35082659-1094128F-698F-4CD1-842E-2FAD52F51259Q35709085-B31C36C1-CBB1-4018-9E75-CF846E14265EQ35799595-197437AC-0D3F-4105-9405-F96671AC540EQ35869624-E8DB8842-D919-4BDA-B7AF-78F43CAB7243Q36536068-C6C4B2A7-C523-48CB-99FE-62120B3800E8Q37416059-D23EA6B9-5D0E-49D7-A220-71B49820D4FBQ37430778-5707E84B-554A-4C8A-BEF5-C487DF203985Q37634929-04AC7E86-D713-42F3-8500-F68E62B971F2Q39048348-8C0C9506-860C-4AA1-9DE1-4450A0E6E00FQ46223563-33A9512F-F77F-43C4-9800-D2635554CAABQ48682358-6A9E177A-2B0C-4B49-A274-C065AA99FCD9Q51357183-DDE6694C-8B8C-411E-9D9C-741D552DDEFBQ54672383-B577F2A0-13A7-465E-A8EE-BBD482EA3531Q58007150-0129A651-6F96-4DC5-8560-C328AFCB2FD0
P2860
Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@ast
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@en
type
label
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@ast
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@en
prefLabel
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@ast
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@en
P2093
P1433
P1476
Are plasma VEGF and its solubl ...... al data from the SAPHIR study.
@en
P2093
A Sandhofer
B Paulweber
J R Patsch
P Schratzberger
R Kirchmair
T Tatarczyk
P304
P356
10.1016/J.ATHEROSCLEROSIS.2009.01.031
P577
2009-02-03T00:00:00Z